Menogaril in the treatment of relapsed multiple myeloma
| Autor: | Julia M. Cruz, William L. Ramseur, Sreenivas M. Reddy, William B. Herring, R. C. Brown, Don V. Jackson, Robert L. Capizzi, Patricia J. Zekan, Howell B. Dalton, Frederick Richards, John A. Lusk, Mark Allen O'Rourke, Richard A. Brodkin, Hyman B. Muss, L. Douglas Case |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Analgesic Antineoplastic Agents Drug Administration Schedule chemistry.chemical_compound Stable Disease Immunopathology medicine Humans Pharmacology (medical) Multiple myeloma Pharmacology Chemotherapy business.industry Cancer Menogaril medicine.disease Surgery Oncology chemistry Nogalamycin Toxicity Drug Evaluation Multiple Myeloma business |
| Zdroj: | Investigational New Drugs. 10:35-37 |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1007/bf01275478 |
| Popis: | Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink